letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...4243444546474849505152...100101»
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  APPOSE: Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis (clinicaltrials.gov) -  Oct 6, 2021   
    P2,  N=60, Recruiting, 
    Future work is warranted to investigate hERG expression as a potential biomarker to predict the therapeutic potential of hERG inhibitors in GBM. Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  cisplatin / Generic mfg.
    Journal:  Antiproliferative activity, enzymatic inhibition and apoptosis-promoting effects of benzoxazole-based hybrids on human breast cancer cells. (Pubmed Central) -  Oct 2, 2021   
    Doxorubicin, cisplatin and 2-(4-aminophenyl)benzothiazole (CJM 126) were used as references...Compound 7a showed inhibition of EGFR comparable to that of erlotinib while compound 8e exhibited nearly half the inhibitory activity of erlotinib towards EGFR and was more potent inhibitor of ARO than letrozole...The predicted docking studies and in silico chemo-informatic properties of compounds 7a and 8e were appropriate. Compounds 7a and 8e are promising anti-breast cancer agents exhibiting potent apoptosis-promoting properties.
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Endogenous hippocampal, not peripheral, estradiol is the key factor affecting the novel object recognition abilities of female rats. (Pubmed Central) -  Oct 2, 2021   
    To confirm the relationship between hippocampal E2 levels and NOR ability, we inhibited the production of hippocampal E2 via microinjection of letrozole (LTZ; an aromatase inhibitor) into the hippocampi of rats in the control group and 8-week OVX group...The data indicated that a reduction in E2 levels in the hippocampus significantly impaired NOR ability and simultaneously decreased Kalirin-7 levels in the hippocampus. In conclusion, our study strongly demonstrates that hippocampal E2, but not peripheral E2, plays a critical role in NOR ability and that Kalirin-7 may be involved in this mechanism.
  • ||||||||||  letrozole / Generic mfg.
    Endocrine therapy in advanced endometrioid endometrial cancer: a retrospective analysis of clinicopathologic factors () -  Oct 1, 2021 - Abstract #ESGO2021ESGO_582;    
    Letrozole (52%) and progestins (48%) were the most frequently used...Conclusion* The clinical benefit of ET was greater in our cohort compared to prior published reports, possibly due to selection of patients with low grade and ER/PR positive tumors. The use of first-line progestins and lack of oligoprogression requiring radiotherapy were significantly associated with longer PFS in this small cohort.
  • ||||||||||  hydrocortisone / Generic mfg., flutamide / Generic mfg.
    Trial completion date, Trial primary completion date, Combination therapy:  Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia (clinicaltrials.gov) -  Oct 1, 2021   
    P2,  N=62, Active, not recruiting, 
    The use of first-line progestins and lack of oligoprogression requiring radiotherapy were significantly associated with longer PFS in this small cohort. Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  letrozole / Generic mfg.
    Review, Journal:  Letrozole in the management of advanced ovarian cancer: an old drug as a new targeted therapy. (Pubmed Central) -  Sep 30, 2021   
    Letrozole, which has a favorable toxicity profile, seems to assure a prolonged recurrence-free interval, particularly when used as maintenance treatment, in low grade serous ovarian cancer; in recurrent cases it had also led to prolonged disease control. However, the optimal setting and biologically relevant patient population needs to be defined in larger trials.
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Trial completion date, Metastases:  MONARCH plus: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (clinicaltrials.gov) -  Sep 29, 2021   
    P3,  N=463, Active, not recruiting, 
    However, the optimal setting and biologically relevant patient population needs to be defined in larger trials. Trial completion date: Dec 2021 --> Feb 2023
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Clinical, Journal, Real-world evidence:  Real-World Palbociclib Use in HR+/HER2- Advanced Breast Cancer in Canada: The IRIS Study. (Pubmed Central) -  Sep 26, 2021   
    P=N/A
    Trial completion date: Dec 2020 --> Apr 2022 | Trial primary completion date: Sep 2020 --> Apr 2022 Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Biomarker, Clinical, Journal:  Predictive Factors Increasing the Risk of Radiation Toxicity in Patients with Early Breast Cancer. (Pubmed Central) -  Sep 22, 2021   
    Overall, while this resulted in a significantly greater PFS in favour of the AIs, this did not translate into improvement in OS. The use of boost irradiation was associated with increased risk of acute dermatitis, in the contrary; the use of trastuzumab seemed to be protective as observed in this study.
  • ||||||||||  letrozole / Generic mfg., clomifene citrate / Generic mfg.
    Trial completion date, Trial primary completion date:  Pharmacokinetics and Hepatic Safety of EGCG (clinicaltrials.gov) -  Sep 22, 2021   
    P1,  N=36, Recruiting, 
    Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2021 --> Jul 2022 Trial completion date: Oct 2021 --> Jan 2022 | Trial primary completion date: Sep 2021 --> Dec 2021
  • ||||||||||  letrozole / Generic mfg.
    Trial completion:  Administration of Single High Dose Letrozole for Ovulation Induction (clinicaltrials.gov) -  Sep 17, 2021   
    P4,  N=36, Completed, 
    Letrozole application to aged Markhoz bucks provokes reproductive hormonal axis which, in turn, induces enhancement of semen production and quality. Recruiting --> Completed
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date, Combination therapy:  Study of Letrozole in Recurrent Gliomas (clinicaltrials.gov) -  Sep 16, 2021   
    P1,  N=42, Recruiting, 
    Recruiting --> Completed Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Jun 2022
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Gut Metabolites Are More Predictive of Disease and Cohoused States than Gut Bacterial Features in a Polycystic Ovary Syndrome-Like Mouse Model. (Pubmed Central) -  Sep 15, 2021   
    Recently, using a letrozole (LET)-induced mouse model of PCOS, we demonstrated that cohousing was protective against development of metabolic and reproductive phenotypes and showed via 16S amplicon sequencing that this protection correlated with time-dependent shifts in gut bacteria...Network correlation analysis showed strong associations between particular BAs and bacterial species, particularly members of Lactobacillus, and that these correlations were time and treatment dependent. Our results provide novel insights into host-microbe relationships related to hyperandrogenism in females and indicate that focused research into small-molecule control of gut microbial diversity and host physiology may provide new therapeutic options for the treatment of PCOS.
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Effect of vitamin D on experimental model of polycystic ovary syndrome in female rats. (Pubmed Central) -  Sep 15, 2021   
    Preclinical laboratory studies revealed that anastrozole, but not exemestane or letrozole, is a ligand for estrogen receptor a. These findings represent potential steps towards individualized anastrozole therapy. These results holding the promise of beneficial impact of vitamin D administration to PCOS and its associated cardiovascular disorders.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Apristor (onapristone XR) / Context Therap
    Enrollment open, Trial completion date, Trial primary completion date, Circulating tumor DNA, Metastases:  A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer (clinicaltrials.gov) -  Sep 13, 2021   
    P1b,  N=28, Recruiting, 
    These results holding the promise of beneficial impact of vitamin D administration to PCOS and its associated cardiovascular disorders. Not yet recruiting --> Recruiting | Trial completion date: May 2023 --> Sep 2023 | Trial primary completion date: May 2023 --> Sep 2023
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal, IO biomarker:  Super Magnetic Niosomal Nanocarrier as a New Approach for Treatment of Breast Cancer: A Case Study on SK-BR-3 and MDA-MB-231 Cell Lines. (Pubmed Central) -  Sep 11, 2021   
    In the present study, a magnetic niosomal nanocarrier for co-delivery of curcumin and letrozole into breast cancer cells has been designed...The findings of our research show the potential of designing magnetic niosomal formulations for simultaneous targeted delivery of both hydrophobic and hydrophilic drugs into cancer cells in order to enhance their synergic chemotherapeutic effects. These results could open new avenues into the future of nanomedicine and the development of theranostic agents.